Drugs / linvemastat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07191535 | Mar 2027 → Jan 2028 expected | chronic asthma | Foresee Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-20 | Foresee Pharmaceuticals Co., Ltd. | Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor foreseepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | linvemastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07191535 ↗ |
| Action | Inhibit | “Linvemastat works by blocking an enzyme called MMP-12” NCT07191535 ↗ |